Successive AdCom wins for bluebird bio cue encouraging signs for rare disease gene therapies
It’s been a turbulent year for gene therapies targeting rare diseases. Could two recent votes for bluebird bio signal a change in fortune?
By
Follow @WillNewton19
William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, rare diseases, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
It’s been a turbulent year for gene therapies targeting rare diseases. Could two recent votes for bluebird bio signal a change in fortune?
By William NewtonSome FDA panelists cited concerns with the ALS trial design, while others pointed to positive data and the high…
By William NewtonOn Rare Disease Day, Pharmaceutical Technology explores how specialty pharmacies and value-based contracts could shape drug distribution.
By William NewtonSeveral pipeline therapies could shake up the schizophrenia field, but their road through development is unlikely to be an…
By William NewtonMany upper middle-income countries fall between the cracks after a recent landmark contract opened molnupiravir access to 105 countries.
By William Newton and Manasi VaidyaCyanVac’s CVXGA1 is a nasally administered Covid-19 vaccine that uses a parainfluenza virus 5 vector.
By William NewtonIn a crowded antidepressant field, zuranolone’s fast onset and sustained effect might not be enough to mask its so-so…
By William NewtonQuestions about oral molnupiravir's deployment still loom large as clinicians await crucial late-stage trial results.
By William Newton and Manasi VaidyaAs breakthrough mild-to-moderate Covid-19 cases continue to rise, all eyes are on Merck and Ridgeback Biotherapeutics’ antiviral.
By William NewtonThank you for subscribing to Pharmaceutical Technology